Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

176

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Iron Overload

Interventions

DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals